Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.06
LH's Cash to Debt is ranked lower than
57% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. LH: 0.06 )
LH' s 10-Year Cash to Debt Range
Min: 0.02   Max: 0.59
Current: 0.06

0.02
0.59
Equity to Asset 0.32
LH's Equity to Asset is ranked higher than
53% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. LH: 0.32 )
LH' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.63
Current: 0.32

0.14
0.63
Interest Coverage 8.31
LH's Interest Coverage is ranked higher than
55% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. LH: 8.31 )
LH' s 10-Year Interest Coverage Range
Min: 1.24   Max: 22.66
Current: 8.31

1.24
22.66
F-Score: 4
Z-Score: 1.85
M-Score: -2.08
WACC vs ROIC
5.89%
7.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.14
LH's Operating margin (%) is ranked higher than
90% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. LH: 13.14 )
LH' s 10-Year Operating margin (%) Range
Min: -4.39   Max: 19.94
Current: 13.14

-4.39
19.94
Net-margin (%) 6.26
LH's Net-margin (%) is ranked higher than
84% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. LH: 6.26 )
LH' s 10-Year Net-margin (%) Range
Min: -9.16   Max: 12.02
Current: 6.26

-9.16
12.02
ROE (%) 13.06
LH's ROE (%) is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. LH: 13.06 )
LH' s 10-Year ROE (%) Range
Min: -24.07   Max: 28.64
Current: 13.06

-24.07
28.64
ROA (%) 4.66
LH's ROA (%) is ranked higher than
83% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. LH: 4.66 )
LH' s 10-Year ROA (%) Range
Min: -5.98   Max: 11.43
Current: 4.66

-5.98
11.43
ROC (Joel Greenblatt) (%) 57.73
LH's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. LH: 57.73 )
LH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24.64   Max: 137.1
Current: 57.73

-24.64
137.1
Revenue Growth (3Y)(%) 8.50
LH's Revenue Growth (3Y)(%) is ranked higher than
81% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. LH: 8.50 )
LH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.4   Max: 20
Current: 8.5

-21.4
20
EBITDA Growth (3Y)(%) 5.50
LH's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. LH: 5.50 )
LH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.3   Max: 17.6
Current: 5.5

-8.3
17.6
EPS Growth (3Y)(%) 5.00
LH's EPS Growth (3Y)(%) is ranked higher than
77% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. LH: 5.00 )
LH' s 10-Year EPS Growth (3Y)(%) Range
Min: 5   Max: 82.8
Current: 5

5
82.8
» LH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

LH Guru Trades in Q2 2014

Paul Tudor Jones 7,020 sh (New)
Louis Moore Bacon 3,935 sh (New)
Tom Gayner 15,000 sh (New)
Ray Dalio 31,466 sh (+291.76%)
John Rogers 1,087,739 sh (+5.85%)
Charles Brandes 154,198 sh (+3.68%)
Wallace Weitz 999,816 sh (+0.21%)
Mario Gabelli 4,000 sh (unchged)
First Pacific Advisors 84,500 sh (unchged)
John Hussman 62,900 sh (unchged)
Larry Robbins Sold Out
David Dreman Sold Out
Jeff Auxier 4,630 sh (-3.14%)
Westport Asset Management 140,000 sh (-6.67%)
Scott Black 79,092 sh (-22.57%)
Richard Pzena 1,654,529 sh (-26.69%)
Chris Davis 6,747,256 sh (-29.99%)
Jeremy Grantham 213,871 sh (-77.86%)
Joel Greenblatt 2,725 sh (-95.40%)
» More
Q3 2014

LH Guru Trades in Q3 2014

Jim Simons 238,200 sh (New)
Joel Greenblatt 317,530 sh (+11552.50%)
Ray Dalio 54,536 sh (+73.32%)
John Rogers 1,389,464 sh (+27.74%)
First Pacific Advisors 99,500 sh (+17.75%)
Charles Brandes 165,695 sh (+7.46%)
John Hussman 62,900 sh (unchged)
Westport Asset Management 140,000 sh (unchged)
Jeff Auxier 4,630 sh (unchged)
Tom Gayner 15,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Louis Moore Bacon Sold Out
Wallace Weitz 988,891 sh (-1.09%)
Richard Pzena 1,558,296 sh (-5.82%)
Chris Davis 5,989,780 sh (-11.23%)
Scott Black 69,949 sh (-11.56%)
Paul Tudor Jones 4,047 sh (-42.35%)
Jeremy Grantham 122,271 sh (-42.83%)
» More
Q4 2014

LH Guru Trades in Q4 2014

Steven Cohen 123,800 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 13,705 sh (+238.65%)
Jim Simons 597,100 sh (+150.67%)
Ray Dalio 70,036 sh (+28.42%)
Scott Black 74,051 sh (+5.86%)
Wallace Weitz 996,606 sh (+0.78%)
Chris Davis 5,928,873 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Westport Asset Management Sold Out
John Hussman Sold Out
Tom Gayner Sold Out
John Rogers 1,386,680 sh (-0.20%)
Chris Davis 5,928,873 sh (-1.02%)
Jeff Auxier 4,580 sh (-1.08%)
Joel Greenblatt 284,471 sh (-10.41%)
Jeremy Grantham 91,180 sh (-25.43%)
Charles Brandes 117,707 sh (-28.96%)
Richard Pzena 830,648 sh (-46.70%)
First Pacific Advisors 50,400 sh (-49.35%)
» More
Q1 2015

LH Guru Trades in Q1 2015

Caxton Associates 3,000 sh (New)
John Keeley 10,760 sh (New)
John Hussman 90,000 sh (New)
Ray Dalio 96,536 sh (+37.84%)
Mario Gabelli 5,000 sh (+25.00%)
John Rogers 1,404,802 sh (+1.31%)
First Pacific Advisors 50,400 sh (unchged)
Louis Moore Bacon Sold Out
Charles Brandes Sold Out
Steven Cohen Sold Out
Scott Black 73,891 sh (-0.22%)
Richard Pzena 728,078 sh (-12.35%)
Paul Tudor Jones 10,793 sh (-21.25%)
Chris Davis 4,443,459 sh (-25.05%)
Wallace Weitz 746,258 sh (-25.12%)
Jeff Auxier 3,380 sh (-26.20%)
Jeremy Grantham 39,680 sh (-56.48%)
Jim Simons 250,605 sh (-58.03%)
Joel Greenblatt 104,024 sh (-63.43%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Laboratory Corp of America Hldgs

John Rogers Comments on Laboratory Corp. of America Holdings - May 07, 2014

We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Laboratory Corp of America Hldgs

John Hussman Increases Portfolio in 1Q2015
John Hussman (Trades, Portfolio) is known for his negative thoughts on the Federal Reserve and the U.S. Treasury. He has been named the "Prophet of Doom" because he predicted the financial crisis of 2008 and says there is another to come that will be much worse. Read more...
Westport Buys Apparel Retailer Express During Q4
Andrew J. Knuth founded Westport Asset Management (Trades, Portfolio) in 1983 with a focus on investing in small-cap companies for institutional clients. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Top Five Guru-Owned Mid Cap Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.20
LH's P/E(ttm) is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 26.20 )
LH' s 10-Year P/E(ttm) Range
Min: 12.98   Max: 27.47
Current: 26.2

12.98
27.47
Forward P/E 14.06
LH's Forward P/E is ranked higher than
96% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 14.06 )
N/A
PE(NRI) 25.60
LH's PE(NRI) is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 25.60 )
LH' s 10-Year PE(NRI) Range
Min: 12.97   Max: 27.46
Current: 25.6

12.97
27.46
P/B 2.60
LH's P/B is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. LH: 2.60 )
LH' s 10-Year P/B Range
Min: 2.6   Max: 5.41
Current: 2.6

2.6
5.41
P/S 1.70
LH's P/S is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. LH: 1.70 )
LH' s 10-Year P/S Range
Min: 1.33   Max: 2.97
Current: 1.7

1.33
2.97
PFCF 30.90
LH's PFCF is ranked higher than
83% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 30.90 )
LH' s 10-Year PFCF Range
Min: 9.15   Max: 32.44
Current: 30.9

9.15
32.44
POCF 19.86
LH's POCF is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 19.86 )
LH' s 10-Year POCF Range
Min: 7.45   Max: 21.26
Current: 19.86

7.45
21.26
EV-to-EBIT 22.02
LH's EV-to-EBIT is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 22.02 )
LH' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 22
Current: 22.02

8.8
22
PEG 4.34
LH's PEG is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 4.34 )
LH' s 10-Year PEG Range
Min: 0.82   Max: 8.39
Current: 4.34

0.82
8.39
Shiller P/E 21.30
LH's Shiller P/E is ranked higher than
95% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 21.30 )
LH' s 10-Year Shiller P/E Range
Min: 16.03   Max: 33.49
Current: 21.3

16.03
33.49
Current Ratio 1.65
LH's Current Ratio is ranked higher than
58% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. LH: 1.65 )
LH' s 10-Year Current Ratio Range
Min: 0.47   Max: 3.64
Current: 1.65

0.47
3.64
Quick Ratio 1.52
LH's Quick Ratio is ranked higher than
60% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. LH: 1.52 )
LH' s 10-Year Quick Ratio Range
Min: 0.44   Max: 3.45
Current: 1.52

0.44
3.45
Days Inventory 13.10
LH's Days Inventory is ranked higher than
94% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. LH: 13.10 )
LH' s 10-Year Days Inventory Range
Min: 9.77   Max: 14.31
Current: 13.1

9.77
14.31
Days Sales Outstanding 67.97
LH's Days Sales Outstanding is ranked higher than
76% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. LH: 67.97 )
LH' s 10-Year Days Sales Outstanding Range
Min: 44.64   Max: 110.1
Current: 67.97

44.64
110.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
LH's Price/DCF (Projected) is ranked higher than
98% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 1.00 )
LH' s 10-Year Price/DCF (Projected) Range
Min: 0.68   Max: 6.11
Current: 1

0.68
6.11
Price/Median PS Value 1.00
LH's Price/Median PS Value is ranked higher than
84% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. LH: 1.00 )
LH' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 1.73
Current: 1

0.07
1.73
Price/Peter Lynch Fair Value 5.00
LH's Price/Peter Lynch Fair Value is ranked higher than
89% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LH: 5.00 )
LH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.86   Max: 5.23
Current: 5

0.86
5.23
Earnings Yield (Greenblatt) 4.50
LH's Earnings Yield (Greenblatt) is ranked higher than
83% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. LH: 4.50 )
LH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 11.3
Current: 4.5

4.5
11.3
Forward Rate of Return (Yacktman) 10.38
LH's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. LH: 10.38 )
LH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.3   Max: 23.6
Current: 10.38

8.3
23.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ALR, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs, founded in 1971, is an independent clinical laboratory company in the United States. Since the Company's founding, it has grown into a national network of 39 primary laboratories and over 1,750 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Company's strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Primary Care, Obstetrics-Gynecology, Specialty Medicine (e.g., Infectious Disease, Endocrinology, Gastroenterology and Rheumatology), Oncology and Hospitals. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
» More Articles for LH

Headlines

Articles On GuruFocus.com
John Hussman's Top Five New Buys in the First Quarter May 12 2015 
John Hussman Increases Portfolio in 1Q2015 May 04 2015 
Laboratory Corporation of America Holdings Q4 Earnings Beat Market Expectations Feb 24 2015 
Westport Buys Apparel Retailer Express During Q4 Feb 11 2015 
Investment Ideas from Guy Spier - Part 2 Jan 07 2015 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Tom Gayner’s Top 5 New Portfolio Picks Aug 11 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
John Rogers Comments on Laboratory Corp. of America Holdings May 07 2014 

More From Other Websites
LabCorp, ORIG3N Collaborate for Special Stem Cell Storage - Analyst Blog May 21 2015
LabCorp Expands HCV Resistance Tests, Adds 2 New Assays - Analyst Blog May 19 2015
ORIG3N™ Announces Strategic Collaboration with LabCorp May 19 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure May 18 2015
LabCorp Announces Full Portfolio of Hepatitis C Virus Drug Resistance Assays May 18 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Submission of Matters to a Vote of Security... May 15 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure May 14 2015
Unicorns that earn billions by making real things May 13 2015
Is STERIS' (STE) Stock Worth Adding to Your Portfolio Now? - Analyst Blog May 12 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure May 12 2015
LabCorp is Scheduled to Present at the UBS Global Healthcare Conference May 12 2015
LabCorp is Scheduled to Present at the UBS Global Healthcare Conference May 12 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K/A, Financial Statements and Exhibits May 08 2015
Theranos jump-starts consumer lab testing May 07 2015
10-Q for Laboratory Corp. of America Holdings May 06 2015
LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 06 2015
The Zacks Analyst Blog Highlights: Celgene, Laboratory Corp. of America Holdings, Quest Diagnostics... May 06 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure May 06 2015
LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 06 2015
Laboratory Corp (LH) Enters Oversold Territory - Tale of the Tape May 06 2015
Beyond Pharma: 3 Healthcare Choices - Analyst Blog May 05 2015
John Hussman Increases Portfolio in 1Q2015 May 04 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 10-Q, Quarterly Report May 04 2015
Trying to explain the strange moves Wed morning Apr 29 2015
Laboratory Corporation of America® Holdings Announces 2015 First Quarter Results and Raises 2015... Apr 27 2015
LabCorp tops Street 1Q forecasts Apr 27 2015
Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as... Apr 21 2015
Bode Technology Supports Identification of Missing Persons in Cyprus Using DNA Apr 09 2015
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Apr 01 2015
LabCorp Completes Acquisition of Covance Mar 20 2015
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest Mar 12 2015
LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference Mar 03 2015
Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and... Feb 20 2015
LabCorp tops Street 4Q forecasts Feb 20 2015
LabCorp Announces Proposed Sale of Senior Notes Jan 21 2015
Covance Sets February 18, 2015 As Date of Special Stockholder Meeting To Vote On Its Proposed... Jan 12 2015
LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
LabCorp Introduces a Test to Identify Enterovirus D-68 (EV-D68) Dec 18 2014
LabCorp Named Laboratory Service Provider of the Pro Football Legends Dec 17 2014
Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance Dec 16 2014
LabCorp Announces Acquisition of Bode Technology Dec 05 2014
LabCorp Completes Acquisition of LIPOSCIENCE Nov 21 2014
US stocks finish flat on mixed data Nov 03 2014
LabCorp to pay $6.1 billion for drug trial company Covance Nov 03 2014
Good US manufacturing data fails to boost stocks Nov 03 2014
US pre-open: S&P, Dow to pull back from records as Chinese data weighs Nov 03 2014
LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare... Nov 03 2014
LabCorp tops Street 3Q forecasts Oct 28 2014
Laboratory Corporation of America® Holdings Announces 2014 Third Quarter Results and Increases 2014... Oct 28 2014
BUZZ-U.S. Stocks on the Move-Apple, coal stocks, BlackHawk, Cleco, Swift Sep 25 2014
US STOCKS-Cantor turns bearish on U.S. equities Sep 25 2014
US STOCKS-Wall St loses ground after mixed economic data Sep 25 2014
US STOCKS-Wall St to open modestly lower after data Sep 25 2014
BUZZ-U.S. Stocks on the Move-Magnum Hunter, Yahoo, Aixtron, Hasbro, Pacira Sep 25 2014
US STOCKS-Futures little changed ahead of data flurry Sep 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK